메뉴 건너뛰기




Volumn 16, Issue 6 SUPPL., 2013, Pages

Value-based assessment of pharmacodiagnostic testing from early stage development to real-world use

Author keywords

biomarkers; drug industry; economics; personalized medicine; pharmacodiagnostics

Indexed keywords

BIOLOGICAL MARKER; WARFARIN;

EID: 84884193216     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.06.007     Document Type: Article
Times cited : (6)

References (35)
  • 1
    • 80052639545 scopus 로고    scopus 로고
    • Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: A meta-analysis
    • L.S. Elias-Sonnenschein, W. Viechtbauer, and I.H. Ramakers Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis J Neurol Neurosurg Psychiatry 82 2011 1149 1156
    • (2011) J Neurol Neurosurg Psychiatry , vol.82 , pp. 1149-1156
    • Elias-Sonnenschein, L.S.1    Viechtbauer, W.2    Ramakers, I.H.3
  • 2
    • 84555195438 scopus 로고    scopus 로고
    • CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis
    • M.V. Holmes, P. Perel, and T. Shah CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis JAMA 306 2011 2704 2714
    • (2011) JAMA , vol.306 , pp. 2704-2714
    • Holmes, M.V.1    Perel, P.2    Shah, T.3
  • 3
    • 84884179049 scopus 로고    scopus 로고
    • EMA Accessed February 19, 2013
    • EMA. Biomarkers. Available from: http://www.ema.europa.eu/ema/index.jsp? curl=pages/special-topics/general/general-content-000349.jsp. [Accessed February 19, 2013].
    • Biomarkers
  • 4
    • 84884172891 scopus 로고    scopus 로고
    • FDA. Biomarker Qualification Program. [Accessed February 19, 2013]
    • FDA. Biomarker Qualification Program. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DrugDevelopmentToolsQualificationProgram/ucm284076.htm. [Accessed February 19, 2013].
  • 5
    • 73349091534 scopus 로고    scopus 로고
    • A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
    • S. Salloway, R. Sperling, and S. Gilman A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
    • (2009) Neurology , vol.73 , pp. 2061-2070
    • Salloway, S.1    Sperling, R.2    Gilman, S.3
  • 6
    • 84868516038 scopus 로고    scopus 로고
    • Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease
    • V. Coric, C.H. van Dyck, and S. Salloway Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease Arch Neurol 69 2012 1430 1440
    • (2012) Arch Neurol , vol.69 , pp. 1430-1440
    • Coric, V.1    Van Dyck, C.H.2    Salloway, S.3
  • 7
    • 84860447272 scopus 로고    scopus 로고
    • The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials
    • K. Yaffe, M. Tocco, and R.C. Petersen The epidemiology of Alzheimer's disease: laying the foundation for drug design, conduct, and analysis of clinical trials Alzheimers Dement 8 2012 237 242
    • (2012) Alzheimers Dement , vol.8 , pp. 237-242
    • Yaffe, K.1    Tocco, M.2    Petersen, R.C.3
  • 8
    • 77957951112 scopus 로고    scopus 로고
    • Revising the definition of Alzheimer's disease: A new lexicon
    • B. Dubois, H.H. Feldman, and C. Jacova Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
    • (2010) Lancet Neurol , vol.9 , pp. 1118-1127
    • Dubois, B.1    Feldman, H.H.2    Jacova, C.3
  • 9
    • 45749113411 scopus 로고    scopus 로고
    • Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study
    • P.J. Visser Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study Neuroepidemiol 30 2008 254 265
    • (2008) Neuroepidemiol , vol.30 , pp. 254-265
    • Visser, P.J.1
  • 10
    • 84865507195 scopus 로고    scopus 로고
    • Injury markers predict time to dementia in subjects with MCI and amyloid pathology
    • I.A. van Rossum, S.J. Vos, and L. Burns Injury markers predict time to dementia in subjects with MCI and amyloid pathology Neurology 79 2012 1809 1816
    • (2012) Neurology , vol.79 , pp. 1809-1816
    • Van Rossum, I.A.1    Vos, S.J.2    Burns, L.3
  • 11
    • 0037514257 scopus 로고    scopus 로고
    • Decreased b-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease
    • T. Sunderland, G. Linker, and N. Mirza Decreased b-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease JAMA 289 2003 2094 2103
    • (2003) JAMA , vol.289 , pp. 2094-2103
    • Sunderland, T.1    Linker, G.2    Mirza, N.3
  • 12
    • 0141738373 scopus 로고    scopus 로고
    • CSF markers for incipient Alzheimer's disease
    • K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol 2 2003 605 613
    • (2003) Lancet Neurol , vol.2 , pp. 605-613
    • Blennow, K.1    Hampel, H.2
  • 13
    • 17044430985 scopus 로고    scopus 로고
    • CSF biomarkers for mild cognitive impairment and early Alzheimer's disease
    • N. Andreasen, and K. Blennow CSF biomarkers for mild cognitive impairment and early Alzheimer's disease Clin Neurol Neurosurg 107 2005 165 173
    • (2005) Clin Neurol Neurosurg , vol.107 , pp. 165-173
    • Andreasen, N.1    Blennow, K.2
  • 14
    • 67651204382 scopus 로고    scopus 로고
    • CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
    • N. Mattson, H. Zetterberg, and O. Hansson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
    • (2009) JAMA , vol.302 , pp. 385-393
    • Mattson, N.1    Zetterberg, H.2    Hansson, O.3
  • 15
    • 74149089257 scopus 로고    scopus 로고
    • Evaluation of plasma Ab40 and Ab42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
    • O. Hansson, H. Zetterberg, and E. Vanmechelen Evaluation of plasma Ab40 and Ab42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment Neurobiol Aging 31 2010 357 367
    • (2010) Neurobiol Aging , vol.31 , pp. 357-367
    • Hansson, O.1    Zetterberg, H.2    Vanmechelen, E.3
  • 16
    • 34547890294 scopus 로고    scopus 로고
    • CSF tau Ab42 ratio for increased risk of mild cognitive impairment: A follow-up study
    • G. Li, I. Sokal, and J.F. Quinn CSF tau Ab42 ratio for increased risk of mild cognitive impairment: a follow-up study Neurology 69 2007 631 639
    • (2007) Neurology , vol.69 , pp. 631-639
    • Li, G.1    Sokal, I.2    Quinn, J.F.3
  • 17
    • 53849132759 scopus 로고    scopus 로고
    • PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment
    • J. Koivunen, T. Pirttila, and N. Kemppainen PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment Dement Geriatr Cogn Disord 26 2008 378 383
    • (2008) Dement Geriatr Cogn Disord , vol.26 , pp. 378-383
    • Koivunen, J.1    Pirttila, T.2    Kemppainen, N.3
  • 18
    • 84876364640 scopus 로고    scopus 로고
    • Screening for predementia AD: Time-dependent operating characteristics of episodic memory tests
    • C.A. Derby, L.C. Burns, and C. Wang Screening for predementia AD: time-dependent operating characteristics of episodic memory tests Neurology 80 2013 1307 1314
    • (2013) Neurology , vol.80 , pp. 1307-1314
    • Derby, C.A.1    Burns, L.C.2    Wang, C.3
  • 19
    • 84855609188 scopus 로고    scopus 로고
    • Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: A Markov model simulation
    • D. Budd, L.C. Burns, and Z. Guo Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation Clinicoecon Outcomes Res 3 2011 189 195
    • (2011) Clinicoecon Outcomes Res , vol.3 , pp. 189-195
    • Budd, D.1    Burns, L.C.2    Guo, Z.3
  • 20
    • 70349548852 scopus 로고    scopus 로고
    • IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
    • V. Suppiah, M. Moldovan, and G. Ahlenstiel IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy Nat Genet 41 2009 1100 1104
    • (2009) Nat Genet , vol.41 , pp. 1100-1104
    • Suppiah, V.1    Moldovan, M.2    Ahlenstiel, G.3
  • 21
    • 70349533037 scopus 로고    scopus 로고
    • Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
    • Y. Tanaka, N. Nishida, and M. Sugiyama Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C Nat Genet 4 2009 1105 1109
    • (2009) Nat Genet , vol.4 , pp. 1105-1109
    • Tanaka, Y.1    Nishida, N.2    Sugiyama, M.3
  • 22
    • 38649090347 scopus 로고    scopus 로고
    • Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
    • A. Mangia, N. Minerva, and D. Bacca Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial Hepatology 47 2008 43 50
    • (2008) Hepatology , vol.47 , pp. 43-50
    • Mangia, A.1    Minerva, N.2    Bacca, D.3
  • 23
    • 33646590308 scopus 로고    scopus 로고
    • Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
    • D.M. Jensen, T.R. Morgan, and P. Marcellin Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy Hepatology 43 2006 954 960
    • (2006) Hepatology , vol.43 , pp. 954-960
    • Jensen, D.M.1    Morgan, T.R.2    Marcellin, P.3
  • 24
    • 23244457832 scopus 로고    scopus 로고
    • Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
    • M. von Wagner, M. Huber, and T. Berg Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C Gastroenterology 129 2005 522 527
    • (2005) Gastroenterology , vol.129 , pp. 522-527
    • Von Wagner, M.1    Huber, M.2    Berg, T.3
  • 25
    • 34250320980 scopus 로고    scopus 로고
    • Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
    • J.W. Yu, G.Q. Wang, and L.J. Sun Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin J Gastroenterol Hepatol 22 2007 832 836
    • (2007) J Gastroenterol Hepatol , vol.22 , pp. 832-836
    • Yu, J.W.1    Wang, G.Q.2    Sun, L.J.3
  • 26
    • 23444460553 scopus 로고    scopus 로고
    • Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    • P. Ferenci, M.W. Fried, and M.L. Shiffman Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 2005 425 433
    • (2005) J Hepatol , vol.43 , pp. 425-433
    • Ferenci, P.1    Fried, M.W.2    Shiffman, M.L.3
  • 27
    • 84873427421 scopus 로고    scopus 로고
    • Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model
    • P. McEwan, R. Kim, and Y. Yuan Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model Appl Health Econ Health Policy 11 2013 53 63
    • (2013) Appl Health Econ Health Policy , vol.11 , pp. 53-63
    • McEwan, P.1    Kim, R.2    Yuan, Y.3
  • 28
    • 60849097257 scopus 로고    scopus 로고
    • Estimation of the warfarin dose with clinical and pharmacogenetic data
    • International Warfarin Pharmacogenetics Consortium
    • International Warfarin Pharmacogenetics Consortium T.E. Klein, and R.B. Altman Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 2009 753 764
    • (2009) N Engl J Med , vol.360 , pp. 753-764
    • Klein, T.E.1    Altman, R.B.2
  • 29
    • 47949086046 scopus 로고    scopus 로고
    • Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    • B.F. Gage, C. Eby, and J.A. Johnson Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin Clin Pharmacol Ther 84 2008 326 331
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 326-331
    • Gage, B.F.1    Eby, C.2    Johnson, J.A.3
  • 30
    • 33947227273 scopus 로고    scopus 로고
    • Association of warfarin dose with genes involved in its action and metabolism
    • M. Wadelius, L.Y. Chen, and N. Eriksson Association of warfarin dose with genes involved in its action and metabolism Hum Genet 121 2007 23 34
    • (2007) Hum Genet , vol.121 , pp. 23-34
    • Wadelius, M.1    Chen, L.Y.2    Eriksson, N.3
  • 31
    • 59649117935 scopus 로고    scopus 로고
    • The largest prospective warfarin-treated cohort supports genetic forecasting
    • M. Wadelius, L.Y. Chen, and J.D. Lindh The largest prospective warfarin-treated cohort supports genetic forecasting Blood 113 2009 784 792
    • (2009) Blood , vol.113 , pp. 784-792
    • Wadelius, M.1    Chen, L.Y.2    Lindh, J.D.3
  • 32
    • 77953304931 scopus 로고    scopus 로고
    • Warfarin genotyping reduces hospitalization rates: Results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)
    • R.S. Epstein, T.P. Moyer, and R.E. Aubert Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness study) J Am Coll Cardiol 55 2010 2804 2812
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2804-2812
    • Epstein, R.S.1    Moyer, T.P.2    Aubert, R.E.3
  • 33
    • 84884196169 scopus 로고    scopus 로고
    • Center for Medicare & Medicaid Services Accessed February 19, 2013
    • Center for Medicare & Medicaid Services. National coverage determination for pharmacogenomic testing for warfarin response. Available from: http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId= 333&ncdver=1&bc=BAAAgAAAAAAA&. [Accessed February 19, 2013].
    • National Coverage Determination for Pharmacogenomic Testing for Warfarin Response
  • 34
    • 73949124118 scopus 로고    scopus 로고
    • Personalized medicine: Factors influencing reimbursement
    • L.M. Meckley, and P.J. Neumann Personalized medicine: factors influencing reimbursement Health Policy 94 2010 91 100
    • (2010) Health Policy , vol.94 , pp. 91-100
    • Meckley, L.M.1    Neumann, P.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.